Improvement of clinical course of liver cirrhosis due to chronic hepatitis C after sucessful treatment with direct acting antivirals

• Autores: Cedrón-Cheng, Hugo, Siccha Sinti, Christian, Tagle Arróspide, Martín
• Formato: artículo
• Fecha de Publicación: 2021
• Institución: Sociedad de Gastroenterología del Perú
• Repositorio: Revista de Gastroenterología del Perú
• Lenguaje: español
• OAI Identifier: oai:ojs.revistagastroperu.com:article/1350
• Enlace del recurso: http://www.revistagastroperu.com/index.php/rgp/article/view/1350
• Nivel de acceso: acceso abierto
• Materia: Hepatitis C; Antiviral agents; Fibrosis; liver; Antivirales; Fibrosis hepática

Direct-acting antivirals are new drugs, highly effective and safe against chronic hepatitis C. However, despite of hepatitis C erradication in patients with decompensated liver cirrhosis, their effect in improving the clinical course, reducing liver-related complications and the risk of developing portal hypertension and hepatocellular carcinoma is still controversial. We present two patients with decompensated liver cirrhosis Child B due to hepatitis C who received treatment with direct-acting antiviral drugs. After treatment, and with the confirmation of undetectable viral load – sustained viral response – both patients showed significant improvement in the clinical course of liver cirrhosis – Child A – and a decrease in the amount of liver fibrosis measured with non invasive methods.